Cambient Family Office LLC Buys Shares of 11,421 Merck & Co., Inc. $MRK

Cambient Family Office LLC purchased a new position in Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 11,421 shares of the company’s stock, valued at approximately $1,213,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Chesapeake Wealth Management lifted its holdings in Merck & Co., Inc. by 0.6% during the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after buying an additional 87 shares during the period. South Plains Financial Inc. boosted its position in Merck & Co., Inc. by 0.6% during the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock valued at $1,635,000 after acquiring an additional 89 shares in the last quarter. Syverson Strege & Co increased its holdings in shares of Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock valued at $436,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. increased its holdings in shares of Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after acquiring an additional 93 shares during the period. Finally, Valued Wealth Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 26.9% in the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock valued at $47,000 after acquiring an additional 94 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

NYSE MRK opened at $114.04 on Friday. The firm’s fifty day simple moving average is $116.12 and its two-hundred day simple moving average is $113.60. The firm has a market capitalization of $281.65 billion, a P/E ratio of 32.12, a P/E/G ratio of 2.60 and a beta of 0.21. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the prior year, the business posted $2.22 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MRK. Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. JPMorgan Chase & Co. lifted their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. Barclays began coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price for the company. Finally, UBS Group increased their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an additional indication for CAPVAXIVE, Merck’s pneumococcal vaccine, expanding its use to children and adolescents ages 2 through 17 at increased risk for pneumococcal disease. The expanded label could support longer-term sales growth and reinforces Merck’s vaccine franchise. Article Title
• Neutral Sentiment: Merck also announced broader corporate activity around AI drug discovery with Protillion Biosciences and a global HPV awareness campaign, which may help pipeline development and brand visibility over time but are not immediate revenue drivers. Article Title
• Neutral Sentiment: A separate survey from Merck Animal Health highlighted unmet needs in treating canine allergic skin disease, suggesting future product opportunity, but it is a relatively small and less immediate catalyst for the stock. Article Title
• Negative Sentiment: Despite the FDA win, MRK has still been trading lower recently, reflecting broader weakness in the shares and suggesting investors may be waiting for more evidence that new and existing products can offset slower growth in other parts of the portfolio. Article Title

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.